SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will provide an overview of the company at the following two investor conferences in March:
- Cowen and Company’s 36th Annual Health Care Conference: Exelixis’ presentation is scheduled for 11:20 AM EST / 8:20 AM PST on Tuesday, March 8, 2016 in Boston.
- Barclays Capital’s Global Healthcare Conference: Exelixis’ presentation is scheduled for 11:15 AM EDT / 8:15 AM PDT on Tuesday, March 15, 2016 in Miami.
Each presentation will be webcast live and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. Please connect to the company’s website at least 15 minutes prior to each presentation to ensure adequate time for any software download that may be require to listen to the webcast. Replays will also be available at the same location for at least 14 days.
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, COTELLIC™ (cobimetinib), a selective inhibitor of MEK, has been approved in Switzerland, the United States, the European Union, and Canada, and is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad global development program under a collaboration with Exelixis. For more information, please visit the company’s website at www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks, and COTELLIC is a U.S. trademark.